Newsroom | 16411 results

OXFORD, England--(BUSINESS WIRE)--A new paper, released this week on bioRxiv, introduces hifiasm-ONT, a breakthrough genome assembly algorithm that enables partially phased, near telomere-to-telomere (T2T) assemblies1, using Oxford Nanopore Simplex reads and standard sample prep. Developed by Haoyu Cheng, Han Qu, Heng Li, and Peter Park, with support from Oxford Nanopore’s machine learning and applications teams, this major algorithmic innovation unlocks the length advantage of Oxford Nanopore’...

DUBLIN--(BUSINESS WIRE)--The "Circulating Biomarkers Europe 2025" conference has been added to ResearchAndMarkets.com's offering. This conference focuses on the various classes of circulating biomarkers, Extracellular Vesicles (EVs), Circulating Cell-Free DNA (cfDNA), Circulating Tumour Cells (CTCs), and Circulating RNAs and Oncoproteins. The goal is a deep dive from a scientific perspective providing details of technologies, tools and biological investigations into these biomarker classes and...

ABU DHABI, Emirati Arabi Uniti--(BUSINESS WIRE)--Abu Dhabi ha lanciato l'innovativo cluster dedicato al settore delle scienze della vita, rafforzando la sua posizione di hub globale per la biotecnologia, la tecnologia medica e la sanità digitale. Sviluppato dal Dipartimento per lo Sviluppo Economico di Abu Dhabi, dall'Ufficio per gli Investimenti di Abu Dhabi (ADIO) e dal Dipartimento della Salute di Abu Dhabi, il cluster HELM (Health, Endurance, Longevity, and Medicine) è stato progettato per...

ABU DHABI, Verenigde Arabische Emiraten--(BUSINESS WIRE)--Abu Dhabi heeft het baanbrekende life sciences-cluster gelanceerd, waardoor de positie van het land als een wereldwijde hub voor biotechnologie, MedTech en digitale gezondheid wordt versterkt. Het Health, Endurance, Longevity and Medicine (HELM)-cluster is ontwikkeld door het Abu Dhabi Department of Economic Development, Abu Dhabi Investment Office (ADIO) en het Department of Health – Abu Dhabi, en is ontworpen om innovatie in de gezondh...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 12, 2025, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France....

TORRANCE, Calif.--(BUSINESS WIRE)--Reproductive Partners Medical Group (RPMG), a nationally recognized leader in fertility care and IVF innovation, is proud to announce the relocation of its Redondo Beach clinic to a brand-new, state-of-the-art facility in Torrance, California, beginning April 14th, 2025. After more than 30 years of providing comprehensive fertility care at its Redondo Beach location—the first IVF lab in the South Bay—RPMG is entering a new era of patient-centered fertility car...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs....

WATERTOWN, Mass.--(BUSINESS WIRE)--EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, today announced the appointment of Clare Murray, Ph.D., as Chief Executive Officer. Dr. Murray brings deep experience in corporate strategy and business development, having led multiple transactions with global pharmaceutical and innovative biotechnology companies. Her work forging strategic partnerships with CDMOs aligns directly with EnPlusOne...

DUBLIN--(BUSINESS WIRE)--The "RNA Interference Market by Type, by Application, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering. The global RNA interference (RNAi) market accounted for USD 1.23 billion in 2023 and is expected to reach USD 6.51 billion by 2034 with a CAGR of 16.33% during the forecast period 2024-2034. The market will grow due to rising investments in RNAi research and development, increasing demand for RNAi therapeutics, improvements in RNA...

DUBLIN--(BUSINESS WIRE)--The "Pharmacogenomics Market by Technology, by Application, by End-users, and by Region" report has been added to ResearchAndMarkets.com's offering. The global pharmacogenomics market is poised for rapid expansion, having been valued at USD 15.45 billion in 2023, with expectations to climb to a remarkable USD 52.59 billion by 2034. The market's impressive compound annual growth rate (CAGR) of 11.78% from 2024 to 2034 is attributed to multiple factors, including the surg...